The cancer diagnostic firm Caris Life Sciences is set to list on the NASDAQ today. The company actually priced its IPO at $21 a share. That was above its expected range.Joining us right now is David Dean Halbert. He is Caris Life Scienc's founder, chairman, and CEO. And David, welcome.Thank you, Becky. Uh let's talk a little bit about what your company does because it's really interesting AI using life sciences to try and go after identify tumors and and find unique ways to deal with each of those cancer tu ...

Core Viewpoint - Moleculin Biotech is advancing Annamycin, a drug designed to eliminate cardiotoxicity associated with anthracyclines, which are used to treat approximately 60% of children with cancer [1][2] Group 1: Pediatric Study and FDA Interaction - The FDA has recommended including patients as young as 6 months in the pediatric clinical study of Annamycin, which is a younger age than initially proposed by Moleculin [1][2] - The pediatric study will evaluate Annamycin in combination with Cytarabine as a second-line therapy for pediatric patients with relapsed/refractory acute myeloid leukemia (R/R AML) [1][2] - Moleculin plans to submit an updated Initial Pediatric Study Plan (iPSP) to the FDA later this quarter, with the pediatric clinical study expected to start in the second half of 2027 [3] Group 2: Clinical Trials and Data - The ongoing Phase 3 MIRACLE trial is evaluating Annamycin in combination with Cytarabine for adult patients with R/R AML, with initial data readout anticipated in the second half of 2025 [1][4] - An independent review of study data has shown no cardiotoxicity in 84 adult patients treated with Annamycin, reinforcing its potential for pediatric use [2][6] - The FDA has granted Annamycin Fast Track Status and Orphan Drug Designation for treating R/R AML and soft tissue sarcoma [4] Group 3: Company Overview and Pipeline - Moleculin Biotech is a late-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections [5] - Annamycin, also known as naxtarubicin, is designed to avoid multidrug resistance mechanisms and eliminate cardiotoxicity common with existing anthracyclines [5][6] - The company is also developing other therapeutic candidates, including WP1066 for various cancers and WP1122 for pathogenic viruses [8]

Group 1 - S&T Bank announced a donation of over $117,000 to Alex's Lemonade Stand Foundation (ALSF) for 2025, continuing its fundraising efforts that began in 2023 [1] - The bank hosted 72 lemonade stands across Pennsylvania and Ohio from May 31 to June 7, 2025, and has exceeded its fundraising goals for three consecutive years [1][4] - ALSF has raised over $300 million to fund research, support families, and raise awareness for childhood cancer since its inception [3] Group 2 - S&T Bancorp, Inc. is a $9.7 billion bank holding company headquartered in Indiana, Pennsylvania, and trades on NASDAQ under the symbol STBA [5] - The principal subsidiary, S&T Bank, was established in 1902 and operates in Pennsylvania and Ohio [5]

Company Overview - Quest Diagnostics Inc. (DGX) has announced a collaboration with The University of Texas MD Anderson Cancer Center to enhance cancer risk assessment and screening [1][5] - The company currently has a market capitalization of $20.12 billion [4] Collaboration Details - The partnership will focus on developing a laboratory-developed blood test based on circulating protein biomarkers linked to high cancer risk, including cancers such as colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal, and stomach [2][5] - Quest Diagnostics will utilize a developmental license for the Multi-Cancer Stratification Test (MCaST) technology developed by MD Anderson, which is based on extensive clinical research involving tens of thousands of individuals [5] Market Performance - Following the announcement, DGX shares increased by 2.6%, closing at $182.07, and have seen a total gain of 31.3% over the past year [3][10] - The company is expected to see an 8.6% growth in earnings from 2024 to 2025, with a historical earnings beat of 2% on average over the last four quarters [4] Industry Insights - The global cancer diagnostics market was valued at $109.6 billion in 2024 and is projected to grow at a compound annual growth rate of 6.1% through 2030, driven by rising cancer prevalence and advancements in diagnostic technologies [11] - Only 51% of U.S. adults reported having a routine medical appointment or cancer screening in the past year, indicating a significant opportunity for new screening methods [7] Future Prospects - If the blood test is successfully validated, Quest Diagnostics may commercialize it for providers in North America by 2026 [6]

Core Viewpoint - Processa Pharmaceuticals has entered into a binding term sheet with Intact Therapeutics for the exclusive option to license PCS12852, a 5-HT4 receptor agonist aimed at treating gastroparesis and other gastrointestinal motility disorders [1][3]. Financial Terms - Processa is set to receive a $2.5 million option exercise fee, up to $20 million in development and regulatory milestone payments, and over $432.5 million in commercial milestone payments based on net product sales [2][8]. - Intact will pay Processa a double-digit royalty on worldwide net sales of licensed products, excluding South Korea, and provide an equity stake of 3.5% in Intact upon closing [2][8]. Clinical Significance - PCS12852 has shown a favorable safety and efficacy profile in clinical studies, particularly in a Phase 2a trial for diabetic gastroparesis, a condition with limited treatment options [3][4]. - The drug is designed to restore normal gastric emptying without the cardiovascular and central nervous system side effects associated with older agents in this class [3]. Strategic Partnership - The partnership is expected to unlock the value of Processa's non-oncology assets while focusing on developing next-generation cancer therapies [3]. - Intact Therapeutics aims to address significant unmet clinical needs in gastrointestinal diseases, enhancing patient quality of life through innovative therapies [3][5]. Company Background - Intact Therapeutics is a clinical-stage biopharmaceutical company focused on next-generation therapies for gastrointestinal diseases, leveraging proprietary thermal hydrogel technology [5]. - Processa Pharmaceuticals specializes in developing next-generation cancer drugs with improved safety and efficacy, modifying existing FDA-approved oncology therapies [7].

NASDAQ: LNTH Lantheus Investor Presentation BUILDING ON OUR FOUNDATION TO POWER THE FUTURE OF RADIOPHARMACEUTICALS 2025 Truist Securities MedTech Conference June 17, 2025 © 2025 Lantheus. All rights reserved. Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor ...

Core Viewpoint - Relmada Therapeutics has appointed Dr. Raj S. Pruthi as Chief Medical Officer-Urology to advance the development of NDV-01, a novel therapy for non-muscle invasive bladder cancer (NMIBC), with a Phase 3 trial expected to begin in the first half of 2026 [2][4]. Company Overview - Relmada Therapeutics is a clinical-stage biotechnology company focused on innovative therapies for oncology and central nervous system conditions [11]. - The lead program, NDV-01, is designed for the treatment of NMIBC and aims to address significant unmet medical needs in this area [11]. Appointment of Dr. Raj S. Pruthi - Dr. Pruthi brings over 25 years of experience in urologic oncology, clinical trials, and robotic surgery, having previously served as Chief Medical Officer at enGene Holdings Inc. and Global Medical Affairs leader at Johnson and Johnson [3][5]. - His expertise includes developing practice guidelines for NMIBC and executing global clinical studies for bladder cancer treatments [3][6]. NDV-01 Program - NDV-01 is a sustained-release formulation of gemcitabine and docetaxel, designed for intravesical administration, allowing for gradual drug release over 10 days [9]. - The formulation aims to enhance local exposure while minimizing systemic toxicity and is designed for in-office administration in under 10 minutes without the need for anesthesia [9]. - Positive initial Phase 2 data presented at the AUA 2025 indicated impressive response rates and favorable tolerability for NDV-01 [4][10]. Market Opportunity - NMIBC accounts for approximately 75% of all bladder cancer cases, with a high recurrence rate of 50-75% over seven years, indicating a significant market opportunity for effective treatments [10]. - With over 600,000 prevalent cases in the U.S. and limited treatment options, NDV-01 has the potential to serve as a frontline or salvage therapy across multiple NMIBC subtypes [10].

ORION CORPORATION PRESS RELEASE 17 JUNE 2025 at 9.00 EEST Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). Under the extended agreement, Orion gains access to Glykos’ proprietary ADC technologies with the potential ...

Breast Cancer Statistics and Screening Challenges - Globally, breast cancer caused 670,000 deaths in 2022, with 11,500 deaths in the UK, equating to 32 deaths per day, and cases are predicted to rise to 70,000 by 2040 [1] - While death rates are falling by 44% due to interventions, better screening, and treatments, low screening uptake remains a concern, especially among underserved populations [1] - NHS backlogs, exacerbated by decades of underfunding and COVID-19, contribute to reduced resources and disproportion between screenings needed and available radiologists and mammographic equipment [1] - Accessibility problems are significantly worse for underserved populations, with cultural unacceptability, invasiveness, fear of radiation, and pain deterring women from undergoing mammography [1] - A survey revealed that 21% of 2,000 women cited embarrassment and fear of pain as reasons for avoiding screening [1] Fingerprint-Based Breast Cancer Screening Innovation - A novel fingerprint-based test is proposed as a non-invasive, radiation-free, and painless alternative to mammography, bypassing NHS backlogs and resource constraints [1] - The technology utilizes mass spectrometry (MALDI) to analyze molecular patterns in fingerprints, identifying proteins indicative of an individual's state, including potential biomarkers for breast cancer [1] - Research demonstrated the ability to differentiate between male and female fingerprints with 86% accuracy by analyzing protein profiles [2] - A study involving 135 samples from 15 women showed that a machine learning algorithm could distinguish between early breast cancer, benign conditions, and metastatic cancer with 97.8% accuracy [2] - The fingerprint test aims to reduce NHS costs, increase accessibility (potentially at GP practices or at home), improve compliance, and ultimately save lives [2]

[Music] Is there anyone here who hasn't experienced loss. Loss comes for all of us repeatedly yet we all talk about it in hushed whispers. We say words like cancer and death behind closed doors, fearing to attract them to us.In fact, we sculpt a public image with full filled with our celebrations, our love and prosperity. Me too. For most of my life, this was my public image.I shared with the world the things that I felt I should be proud of. Yet what I would like to suggest to you today is that loss is a s ...